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Over 5 million individuals are afflicted with heart failure in the United States per year. [1] 
Current guidelines based on the MADIT- I and II, MUSTT and SCDHeFT trials recommend 
the use of pharmacologic as well as implantable cardioverter defibrillator (ICD) therapy as 
Class I indications for the prevention of sudden cardiac death (SCD) in a subgroup of patients 
(depending on their ejection fraction, NYHA class, and a variety of other parameters). [2-7] 
However, despite these guidelines, the use of ICDs has been reported as suboptimal in prior 
publications as well as in the article by Pillarisetti, et al in this issue of the Journal. [8]        
Pillarisetti, et al present the current state of ICD use in their single center experience, noting 
profound underutilization of ICDs as a prophylactic treatment for sudden cardiac death. [8] 
They subsequently went on to carefully examine the reasons behind ICD underuse. In their 
retrospective study, they found that though pharmacologic treatment  of SCD with a beta-
blocker,  angiotensin  cardioverter  enzyme  inhibitory/angiotensin  receptor  blocker 
(ACE/ARB),  diuretics  and  aldosterone  antagonists  (AA)  was  nearly  perfect,  the 
implementation of ICDs for treatment of patients who met ICD Class I indications was only 
1/3  of  the  expected  rate.  [2]                                           
Over-  or  under-utilization?                                      
Prior to delving into the data, it is important to put into perspective the last several years in 
electrophysiology which have proven complicated for many ICD implanters. After Al-Khatib, 
et  al  suggested  a  high  rate  of  inappropriate  ICD  implantation  in  the  United  Stated, 
investigations by the Department of Justice into the practice patterns of implanting centers 
became more common. [9-11] However, one clear limitation of that seminal publication was 
precisely  how  "appropriateness"  was  defined  -  namely  by  criteria  advanced  by 
Medicare/insurers rather than strictly abiding by guidelines. The issue at hand is that, while all 
legislation  to  identify  appropriate  versus  inappropriate  is  well-meaning,  the  number  of 
different guidelines to which physicians must  refer  is  extensive  and  can  prove  to  be  near 
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impossible for the average, busy clinician to navigate through. Nowadays, there are consensus 
guidelines, appropriate use criteria, Medicare reimbursement guidelines, criteria put forth by 
the Department of Justice, and assessment tools by the National Cardiovascular Data Registry 
that  may  inform the  clinician  about  ICD appropriateness.  These  varied  resources  do  not 
perfectly overlap. Furthermore, while in the guidelines statements that something should be 
done (i.e. a Class I indication) or should not be done (i.e. a Class III indication) are present, an 
ICD  implant  for  an  indication  not  specifically  mentioned  in  those  guidelines  does  not 
necessarily mean that an ICD in such a patient is inappropriate.                                        
This difficulty in clinical decision making is highlighted best by the appropriate use criteria, 
in which a large number of considerations based on comorbidities and other less clear-cut 
cases not specifically mentioned in the guidelines were adjudicated to fall within the realm of 
"may be appropriate" - suggesting a lack of evidence for or against.[7] Thus, despite a wealth 
of data and ongoing research into which patient populations would best meet criteria for an 
ICD implant, for many patients, decision-making is still quite murky.                               
How  do  we  determine  underutilization?                                      
The patient population probably best understood in terms of primary prevention indications 
for ICDs is that of patients with heart failure due to reduced ejection fraction (i.e. <35%). 
Putting  the article  by Pillarisetti,  et  al  in  context  requires  a  close review of  who did not 
receive an ICD and why.[8] Amongst patients  who did not receive ICD implants in their 
study, there are cohorts of patients who should perhaps never have qualified. For example, 
20.4% (those  who had improvement  in  their  EF and those  who died  within  one  year  of 
diagnosis or who were expected to have a low one year survival) should not have received an 
ICD according to current guidelines and appropriate use criteria. One can debate the fact that 
the currently accepted timeline to wait for EF improvement after instituting guideline directed 
medical therapy is 3 months. However, that time cut-off was based on an arbitrary time period 
used in SCD-HeFT and not based on any systematic data of the amount of time necessary to 
see EF recovery. In fact, recently published data suggests that perhaps 3 months is not long 
enough to wait for EF recovery given that nearly 1/3 of patients implanted with a primary 
prevention ICD may demonstrate sufficient EF recovery at the time of generator change (i.e. 
years after diagnosis) to no longer qualify.[12] In addition, expected survival of less than 1 
year is considered a contraindication to ICD therapy and, while retrospective, those patients 
who did die within one year likely reflected a group of patients who should never have been 
considered  for  ICD  implantation.                                       
While  the authors also postulate  possible reasons patients  refused an ICD, the number of 
patients  refusing  is  in  keeping  with  prior  published  studies  (22.6%)  and  should  not  be 
considered underutilization since it reflects a patient's right to refuse, though we agree it is 
important  to  understand better  why these patients  refuse.  Furthermore,  there were several 
other  reasons  that  cannot  be  considered  "underutilization"  as  it  seems  from  the  reasons 
offered that the patients were, in fact, not eligible for an ICD (lack of patient followup which 
is  a  class  III  indication  for  ICD  implantation,  active  infection  such  as  osteomyelitis, 
comorbidities precluding implant, etc) which would account for another 19.4% of those not 
implanted. Thus, if it is assumed all patients who received ICDs were appropriate, a total of 
39% of eligible patients did not receive ICDs, largely due to lack of physician discussion with 
the  patient  rather  than  the  much  higher  number  quoted.                             
Why  is  utilization  not  at  expected  levels?                              
There are several reasons for the noted discrepancies in ICD utilization. As Pillarisetti, et al 
point out, [8] one reason may be that patient education and reinforcement of the necessity of 
ICD treatment is lacking. Many patients may have chosen not to pursue an  ICD  due  to 
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misunderstanding the therapy from media reports of recalls (eg, of the Fidelis lead), or out of 
fear of pain from defibrillation from another's experience.[13] In such cases, it is imperative 
for  physicians  to  educate  patients  about  the  truth  of  ICD  therapy  and  dispel  any 
misconceptions.[13]  Modern  devices,  such  as  subcutaneous  ICDs  (which  do  not  require 
implantation of transvenous leads), evolving leadless device technology, improved algorithms 
for  detection  of  ventricular  arrhythmias  to  reduce  the  rate  of  inappropriate  shocks,  and 
research  into  painless  defibrillation  may  also  help  improve  patient  perception  of  ICDs.
The starkest  finding is  that  the  plurality  of  patients  did not  receive  ICDs due to  lack  of 
discussion  by  the  physician.  This  is  a  critical  issue  and  either  reflects  lack  of  provider 
education or other barriers that need to be identified.  Discussion of ICDs, given its clear 
potential  life-saving  benefit  in  patients  with  irreversible  cardiomyopathy,  should  be 
considered  as  much a performance  measure  as  use  of  ACE/ARB or  beta-blockers.  Thus, 
better research into why physicians do not have the discussion with patients is necessary.  
Yet another reason for ICD underutilization may be the imprecise nature of current guidelines 
when  it  comes  to  assessing  appropriateness  of  implantation  in  patients  with  varying 
comorbidities. While the appropriate use criteria (AUC) do allocate an entire section of their 
document to assessing comorbidities and how they impact appropriateness of implantation, 
the majority of the indications are listed in the middle range of "M," suggesting that it is still 
unclear as to whether the patient should be implanted or not. [7,9] This leaves the ultimate 
decision up to the physician and patient, and given that patients can be influenced by outside 
factors (i.e. media), it is not surprising that the ICD implantation rate is low. However, this 
issue can be seen the other way - namely that perhaps more data is needed to better inform 
clinicians  about  which  sub-populations  reflect  patients  in  whom  ICD  should  not  be 
considered - whether due to age, renal failure, or other comorbidities.                         
Future  Innovations                                      
Other more proactive ways to prevent underutilization of ICD in the future involve significant 
changes in the way ICD care is delivered. Creation of simpler, inexpensive and novel devices 
along with integrated preventative ablative therapies and pharmacologic treatments for heart 
failure  are  stepping  stones  for  achieving  this  revolutionized  form  of  SCD  care.  With 
increasing technological advances and the growing prevalence of percutaneously delivered 
devices since its introduction by Sosa et al., [14] epicardial devices that have the potential to 
deliver  painless  defibrillation  to  patients  are  being  generated.  [15]  If  these  devices  are 
successful, then their use may help in decreasing the fear of defibrillation for patients and 
encourage  ICD  implantation.                                                    
While the use of beta blockers, ARBs, and ACE inhibitors are still implemented unanimously 
in  patients  with  heart  failure,  they  have  shown  varying  success.  Newer  agents  with 
angiotensin-neprilysin inhibition are showing even more promise in managing HF. [16] The 
PARADIGM-HF  trial  laid  out  a  novel  approach  to  heart-failure  therapy  consisting  of 
angiotensin-receptor  blockade  and  neprilysin  inhibition  with  LCZ696  (consisting  of  both 
sacubitril  and valsartan).  [17] Their  findings showed that  cardiovascular  mortality  fell  by 
nearly 20% and overall mortality decreased by 16% compared with enalapril. [16] Neprilysin, 
an  endopeptidase  that  metabolizes  peptides,  when  inhibited  is  thought  to  lead  to  the 
degradation of vasoactive peptides, including natriuretic peptides that vasodilate vessels and 
lead to sodium excretion, thereby reducing the load on the heart in patients with HF. [16]
Conclusion
Ultimately, a better understanding of current guidelines coupled with novel ICD devices and 
pharmacological  regimen may be a solution to reducing the rate of ICD under-utilization.
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